Shares in the Aussie biotech company Mesoblast limited (ASX: MSB) continue to fall. In fact, the Mesoblast share price is down 37.0% since Monday’s close to $3.07 per share.
It’s not unusual to see big valuation swings in the biotech space. But at what point does Mesoblast go from a falling knife to a screaming buy?
Why is the Mesoblast share price falling?
A major catalyst for the share price fall has been a report from the United States Food and Drug Administration (FDA).
The US regulator questioned the effectiveness of Mesoblast’s remestemcel-L as a treatment for paediatric patients with steroid-resistant acute graft versus host disease.
The FDA noted concerns over the treatment’s clinical performance ahead of Mesoblast’s meeting with the Oncologic Drugs Advisory Committee (ODAC).
That spooked investors on Tuesday with the Mesoblast share price falling 31.0% lower in one day. That momentum continued on Wednesday as the biotech share slumped a further 8.6% lower.
That means the Mesoblast share price is now down 37.1% since Monday’s close. It can be a dangerous game to buy a share in freefall, but how does the Mesoblast equation stack up?
Is Mesoblast in the buy zone yet?
Investors appear to be pricing in a rejection from the ODAC in tomorrow’s meeting. Given the scepticism expressed by the US FDA, I think that’s probably a fair view to take.
However, I think Mesoblast still has a portfolio of promising candidates. The company is exploring remestemcel-L as a treatment for coronavirus-induced acute respiratory distress syndrome.
The company’s Revascor and MPC-06-ID are also Phase 3 candidates for treating advanced chronic heart failure and degenerative back disc disease, respectively.
I think the Mesoblast share price will continue to be volatile. That’s partly the nature of the game with these make or break, R&D-heavy companies.
However, I still believe there is long-term potential for Mesoblast. Of course, this setback does lower the short-term intrinsic value.
With its extensive pipeline and track record of success though, I think the Mesoblast share price could be a buy at $3.07 per share.
Are there other ASX biotech shares to buy?
If you’re looking for other ASX biotech shares to buy right now, the Polynovo Ltd (ASX: PNV) share price is another strong candidate.
Polynovo’s NovoSorb BTM product continues to kick goals and the biotech group is looking to expand its application.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- Why ASX travel shares like Webjet (ASX:WEB) fell lower on Monday – January 25, 2021 6:08pm
- Why the National Tyre (ASX:NTD) share price is soaring 15% today – January 25, 2021 11:31am
- Why Tesla (NASDAQ:TSLA) shares were last year’s worst short bet – January 25, 2021 9:03am